lorlatinib

lor-LA-ti-nib

Therapeutic Classification: antineoplastics

Pharmacologic Classification: kinase inhibitors

High Alert

Metastatic non-small cell lung cancer (NSCLC) that is positive for anaplastic lymphoma kinase (ALK).

Acts as a tyrosine kinase inhibitor, inhibiting ALK as well as other kinases, including ROS1, resulting in decreased growth of certain malignant cell lines.

Therapeutic effects:

Slowed progression of metastatic NSCLC.

Absorption: 81% absorbed following oral administration.

Distribution: Extensively distributed to tissues.

Metabolism/Excretion: Primarily metabolized in the liver by the CYP3A4 isoenzyme and UGT1A4, with some metabolism by the CYP2C8 and CYP2C19 isoenzymes. 48% excreted in urine (<1% as unchanged drug), 41% in feces (9% as unchanged drug).

Half-Life: 24 hr.

(plasma concentrations)

ROUTE	ONSET	PEAK	DURATION
PO	unknown	2 hr	24 hr

Contraindicated in:

Concurrent use of moderate or strong CYP3A inducers;
OB: Pregnancy;
Lactation: Lactation.

Use Cautiously in:

Hypertension;
Moderate or severe hepatic impairment;
Severe renal impairment (↓ dose);
Rep: Women of reproductive potential and men with female partners of reproductive potential;
Pedi: Safety and effectiveness not established in children.

CV: hypertension, peripheral edema, atrioventricular (AV) block, PR interval prolongation

Derm: rash

EENT: visual changes

Endo: hyperglycemia

F and E: hyperkalemia, hypomagnesemia, hypophosphatemia

GI: ↑amylase, ↑lipase, ↑liver enzymes, constipation, diarrhea, hypoalbuminemia, nausea, vomiting

GU: ↓fertility (males)

Hemat: anemia, lymphopenia, thrombocytopenia

Metab: hypercholesterolemia, hypertriglyceridemia, weight gain

MS: arthralgia, myalgia

Neuro: cognitive changes, dizziness, fatigue, headache, mood disturbances, peripheral neuropathy, sleep disturbances, speech disorders, hallucinations, mental status changes, SEIZURES, SUICIDAL THOUGHTS

Resp: cough, dyspnea, upper respiratory tract infection, INTERSTITIAL LUNG DISEASE (ILD)/PNEUMONITIS

Misc: fever

Drug-drug:

Moderate CYP3A inducers and strong CYP3A inducers, including rifampin, may ↓ effectiveness and ↑ risk of hepatotoxicity; concurrent use with strong CYP3A inducers contraindicated (discontinue strong CYP3A4 inducer for 3 half-lives [3 days] prior to starting lorlatinib); avoid concurrent use with moderate CYP3A inducers (if concurrent use unavoidable, ↓ lorlatinib dose).
Strong CYP3A inhibitors, including itraconazole, may ↑ levels and risk of toxicity; avoid concurrent use; if concurrent use unavoidable, ↓ lorlatinib dose.
May ↓ levels and effectiveness of CYP3A substrates; avoid concurrent use; if concurrent use unavoidable, ↑ CYP3A substrate dose.
May ↓ levels and effectiveness of P-glycoprotein (P-gp) substrates, including fexofenadine; avoid concurrent use; if concurrent use unavoidable, ↑ P-gp substrate dose.

PO (Adults ): 100 mg once daily until disease progression or unacceptable toxicity. Concurrent use of strong CYP3A inhibitor: 75 mg once daily until disease progression or unacceptable toxicity; if dose already ↓ to 75 mg once daily due to adverse reactions, then further ↓ to 50 mg once daily. Concurrent use of moderate CYP3A inducer: 125 mg once daily until disease progression or unacceptable toxicity.

Renal Impairment

PO (Adults ): CCr 15–<30 mL/min: 75 mg once daily until disease progression or unacceptable toxicity.

Tablets: 25 mg; 100 mg

Monitor for signs and symptoms of CNS effects (seizures; hallucinations; changes in cognitive function, mood, speech, mental status, and sleep; suicidal ideation) during therapy. For Grade 1 effects: continue at same dose or hold dose until recovery to baseline. Resume at same dose or at ↓ dose. For Grade 2 or 3 effects: hold dose until Grade 0 or 1. Resume at ↓ dose. For Grade 4: permanently discontinue.
Monitor ECG before starting therapy and periodically thereafter. May cause PR interval prolongation and AV block. If second-degree AV block occurs, hold dose until PR interval <200 msec. Resume at ↓ dose. For 1st occurrence of complete AV block, hold until pacemaker placed or PR interval <200 msec. If a pacemaker is placed, resume at same dose. If no pacemaker is placed, resume at a ↓ dose. If recurrent complete AV block occurs, place pacemaker or permanently discontinue.
Monitor for signs and symptoms of ILD/pneumonitis (worsening dyspnea, cough, and fever) during therapy. If ILD/pneumonitis occur at any grade, immediately hold dose and permanently discontinue.
Monitor BP before starting therapy, after 2 wk, and at least monthly thereafter. If Grade 3 (SBP ≥160 mmHg or DBP ≥100 mmHg; medical intervention indicated; >1 antihypertensive drug, or more intensive therapy than previously used indicated) occurs, hold until ≤Grade 1 (SBP <140 mmHg and DBP <90 mmHg); then resume at same dose. If Grade 3 hypertension recurs, hold until recovery to ≤Grade 1 and resume at a ↓ dose. If adequate hypertension control cannot be achieved with optimal medical management, permanently discontinue. If Grade 4 (life-threatening consequences, urgent intervention indicated) hypertension occurs, hold until recovery to ≤Grade 1 and resume at a ↓ dose or permanently discontinue. If Grade 4 hypertension recurs, permanently discontinue.

Lab Test Considerations:

Verify negative pregnancy test before starting therapy.
- Selection of patients is based on the presence of ALK positivity in tumor specimens. Information on FDA-approved tests for the detection of ALK rearrangements in NSCLC is available at http://www.fda.gov/CompanionDiagnostics.
- Monitor serum cholesterol and triglycerides before starting therapy, 1 and 2 mo after starting, and periodically thereafter. Start or ↑ dose of lipid-lowering agents in patients with hyperlipidemia. For Grade 4 hypercholesterolemia or Grade 4 hypertriglyceridemia: hold until recovery of hypercholesterolemia and/or hypertriglyceridemia to ≤Grade 2. Resume at same dose. If severe hypercholesterolemia and/or hypertriglyceridemia recurs, resume at a ↓ dose.
- Monitor fasting serum glucose before starting therapy and periodically thereafter. If Grade 3 hyperglycemia (>250 mg/dL) occurs despite optimal antihyperglycemic therapy OR Grade 4 hyperglycemia occurs, hold until hyperglycemia is adequately controlled; then resume at ↓ dose. If adequate glycemic control cannot be achieved with optimal medical management, permanently discontinue.

Dose reduction schedule: First dose reduction: 75 mg once daily. Second reduction: 50 mg once daily. Discontinue permanently in patients unable to tolerate 50 mg dose.
PO: Administer once daily, at the same time each day, without regard to food. DNC: Swallow tablets whole; do not crush, break, or chew. Do not ingest if tablet is broken or cracked.

Explain purpose and side effects of medication to patient. Advise patient to read Patient Information before starting therapy. Instruct patient to take as directed at the same time each day. If vomiting occurs, omit dose and take next scheduled dose next day. Take missed doses as soon as remembered up to 4 hr from next dose; do not double doses.
Instruct patient to notify health care professional of all Rx or OTC medications, vitamins, or herbal products being taken and consult health care professional before taking any new medications.
Advise patient to notify health care professional if signs and symptoms of CNS effects, hypertension (headaches, dizziness, blurred vision, chest pain, shortness of breath), hyperglycemia (excessive thirst, frequent urination, feeling very hungry, nausea, feeling weak or tired, feeling confused), or heart problems (feeling dizzy or faint or have abnormal heartbeats) occur.
Advise patient to notify health care professional immediately if signs and symptoms of lung problems (trouble breathing, shortness of breath, cough, fever) occur.
Rep: May cause fetal harm. Advise females of reproductive potential to use effective nonhormonal contraception during and for 6 mo after last dose and to avoid breastfeeding during and for 7 days after last dose. Advise men with female partners of reproductive potential to use effective contraception during and for 3 mo after last dose. May transiently impair male fertility.

Slowed progression of metastatic NSCLC.

Lorbrena

NDC Code

0069- Pfizer Laboratories Div Pfizer Inc
- 0069-0227- Lorbrena
  - 0069-0227-01- 30 TABLET, FILM COATED in 1 BOTTLE (0069-0227-01)

0069- Pfizer Laboratories Div Pfizer Inc
- 0069-0231- Lorbrena
  - 0069-0231-01- 30 TABLET, FILM COATED in 1 BOTTLE (0069-0231-01)

section name header

Pronunciation ⬇

Classifications ⬆ ⬇

Indications ⬆ ⬇

Action ⬆ ⬇

Pharmacokinetics ⬆ ⬇

Time/Action Profile ⬆ ⬇

Contraind./Precautions ⬆ ⬇

Adv. Reactions/Side Effects ⬆ ⬇

Interactions ⬆ ⬇

Route/Dosage ⬆ ⬇

Availability ⬆ ⬇

Assessment ⬆ ⬇

Implementation ⬆ ⬇

Patient/Family Teaching ⬆ ⬇

Evaluation/Desired Outcomes ⬆ ⬇

US Brand Names ⬆ ⬇

Code ⬆